148 related articles for article (PubMed ID: 38284280)
1. CCL2-CCR2 signaling axis in obesity and metabolic diseases.
Wu Y; Ma Y
J Cell Physiol; 2024 Apr; 239(4):e31192. PubMed ID: 38284280
[TBL] [Abstract][Full Text] [Related]
2. CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease.
Parker R; Weston CJ; Miao Z; Corbett C; Armstrong MJ; Ertl L; Ebsworth K; Walters MJ; Baumart T; Newland D; McMahon J; Zhang P; Singh R; Campbell J; Newsome PN; Charo I; Schall TJ; Adams DH
Am J Physiol Gastrointest Liver Physiol; 2018 Apr; 314(4):G483-G493. PubMed ID: 29420066
[TBL] [Abstract][Full Text] [Related]
3. Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments.
Kang YS; Cha JJ; Hyun YY; Cha DR
Expert Opin Investig Drugs; 2011 Jun; 20(6):745-56. PubMed ID: 21466412
[TBL] [Abstract][Full Text] [Related]
4. Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications.
Zhang H; Yang K; Chen F; Liu Q; Ni J; Cao W; Hua Y; He F; Liu Z; Li L; Fan G
Front Immunol; 2022; 13():975367. PubMed ID: 36110847
[TBL] [Abstract][Full Text] [Related]
5. Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury.
Xu P; Zhang F; Chang MM; Zhong C; Sun CH; Zhu HR; Yao JC; Li ZZ; Li ST; Zhang WC; Sun GD
J Neuroinflammation; 2021 Mar; 18(1):64. PubMed ID: 33653377
[TBL] [Abstract][Full Text] [Related]
6. Estrogen promotes progression of hormone-dependent breast cancer through CCL2-CCR2 axis by upregulation of Twist via PI3K/AKT/NF-κB signaling.
Han R; Gu S; Zhang Y; Luo A; Jing X; Zhao L; Zhao X; Zhang L
Sci Rep; 2018 Jun; 8(1):9575. PubMed ID: 29934505
[TBL] [Abstract][Full Text] [Related]
7. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway.
Zhuang H; Cao G; Kou C; Liu T
Oncol Rep; 2018 Jan; 39(1):21-30. PubMed ID: 29115520
[TBL] [Abstract][Full Text] [Related]
8. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.
Xu M; Wang Y; Xia R; Wei Y; Wei X
Cell Prolif; 2021 Oct; 54(10):e13115. PubMed ID: 34464477
[TBL] [Abstract][Full Text] [Related]
9. CCL2-CCR2 Signaling in Disease Pathogenesis.
O'Connor T; Borsig L; Heikenwalder M
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):105-18. PubMed ID: 25772168
[TBL] [Abstract][Full Text] [Related]
10. Targeting the CCL2-CCR2 signaling axis in cancer metastasis.
Lim SY; Yuzhalin AE; Gordon-Weeks AN; Muschel RJ
Oncotarget; 2016 May; 7(19):28697-710. PubMed ID: 26885690
[TBL] [Abstract][Full Text] [Related]
11. Chemokine (C-C Motif) Ligand 2/Chemokine Receptor 2 (CCR2) Axis Blockade to Delay Chondrocyte Hypertrophy as a Therapeutic Strategy for Osteoarthritis.
Wang Z; Wang B; Zhang J; Wu Z; Yu L; Sun Z
Med Sci Monit; 2021 Dec; 27():e930053. PubMed ID: 34876548
[TBL] [Abstract][Full Text] [Related]
12. Gas6 Promotes Inflammatory (CCR2
Laurance S; Bertin FR; Ebrahimian T; Kassim Y; Rys RN; Lehoux S; Lemarié CA; Blostein MD
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1315-1322. PubMed ID: 28450294
[TBL] [Abstract][Full Text] [Related]
13. Targeting the CCL2-CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases.
Gholamalizadeh H; Ensan B; Sukhorukov VN; Sahebkar A
J Pharm Pharmacol; 2024 Jan; 76(2):138-153. PubMed ID: 38127312
[TBL] [Abstract][Full Text] [Related]
14. The chemokine (CCL2-CCR2) signaling axis mediates perineural invasion.
He S; He S; Chen CH; Deborde S; Bakst RL; Chernichenko N; McNamara WF; Lee SY; Barajas F; Yu Z; Al-Ahmadie HA; Wong RJ
Mol Cancer Res; 2015 Feb; 13(2):380-90. PubMed ID: 25312961
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy.
Yang SJ; IglayReger HB; Kadouh HC; Bodary PF
Diabetologia; 2009 May; 52(5):972-81. PubMed ID: 19277603
[TBL] [Abstract][Full Text] [Related]
16. Potentials of C-C motif chemokine 2-C-C chemokine receptor type 2 blockers including propagermanium as anticancer agents.
Yumimoto K; Sugiyama S; Mimori K; Nakayama KI
Cancer Sci; 2019 Jul; 110(7):2090-2099. PubMed ID: 31111571
[TBL] [Abstract][Full Text] [Related]
17. Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model.
Teng KY; Han J; Zhang X; Hsu SH; He S; Wani NA; Barajas JM; Snyder LA; Frankel WL; Caligiuri MA; Jacob ST; Yu J; Ghoshal K
Mol Cancer Ther; 2017 Feb; 16(2):312-322. PubMed ID: 27980102
[TBL] [Abstract][Full Text] [Related]
18. Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Ben-Yehuda H; Arad M; Peralta Ramos JM; Sharon E; Castellani G; Ferrera S; Cahalon L; Colaiuta SP; Salame TM; Schwartz M
Mol Neurodegener; 2021 Jun; 16(1):39. PubMed ID: 34172073
[TBL] [Abstract][Full Text] [Related]
19. CCL2-CCR2 signaling promotes hepatic ischemia/reperfusion injury.
Zhang J; Xu P; Song P; Wang H; Zhang Y; Hu Q; Wang G; Zhang S; Yu Q; Billiar TR; Wang C; Zhang J
J Surg Res; 2016 May; 202(2):352-62. PubMed ID: 27229110
[TBL] [Abstract][Full Text] [Related]
20. CCR2 Chemokine Receptors Enhance Growth and Cell-Cycle Progression of Breast Cancer Cells through SRC and PKC Activation.
Yao M; Fang W; Smart C; Hu Q; Huang S; Alvarez N; Fields P; Cheng N
Mol Cancer Res; 2019 Feb; 17(2):604-617. PubMed ID: 30446625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
